IRCT201504141479N3已完成3 期
The effects of alendronate and Vitamin K Combination versus Alendronate alone on bone mineral density of patients with postmenopausal osteoporosis
Vice president for research, Mashhad University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 45 years 至 65 years（—）
- 性别
- Female
入选标准
- •1- Osteoporosis according to WHO Criteria
- •2-Age:45-65 years
- •3- Postmenopausal women
- •Exclusion criteria
- •1- Secondary Osteoporosis
- •2- Taking anticoagulants
- •3- History of liver and kidney disorders
- •4- History of Bisphosphonates side effects
- •5- People who have contraindications to take calcium and vitamin D
- •6- People who take other anti- osteoporotic medications
- •7- People who needs to use Vit.K in the alendronate group
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Effect of alendronate or calcium plus vitamin D3 on thalassemic osteopathyThalassemic osteopathySLCTR/2008/018Faculty of Medicine, University of Ruhuna20
已完成
不适用
Effect of alendronate and vitamin D on selected bone turnover markers in women with postmenopausal osteoporosis and a high fracture risk; a randomized controlled trialPost-menopausal osteoporosisSLCTR/2018/038
已完成
不适用
Effect of risedronate combined with vitamin K2 in patients with osteoporosis due to the steroid therapyOsteoporosisJPRN-UMIN000006519Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine100
进行中（未招募）
1 期
Vitamin K in OsteoporosisEUCTR2010-022587-12-GBGuy's and St. Thomas' NHS Foundation Trust105
尚未招募
不适用
Combination therapy with alendronate and alphacalcidol for prevention of symptomatic vertebral fracture in elderly patients treated with high-dose glucocorticoid: a multicenter open-label randomized controlled trial.glucocorticoid-induced osteoporosisJPRN-UMIN000004217Society for glucocorticoid-induced osteoporosis200